4min chapter

Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

CHAPTER

HIV AIDS - Is the Nader CD4 Cell Count What Matters?

Everybody in the trial, including those in the original deferred group were offered ART to start by January 1, 2016. They retained 4,436 patients in this additional analysis post 2016. The remaining excess risk was primarily driven by patients that were 35 years of age or less. So it's definitely got me thinking. There still is probably going to spark a lot of research moving forward.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode